Pressmeddelanden, rapporter och bolagsmeddelande för Eevia Health Plc

Eevia Health Plc has announced that the publication of its Q4 2024 interim report will be moved up to February 4, 2025, from the originally scheduled date of February 14, 2025. This change aims to allow insiders, who are currently restricted by a trading ban, to participate in the ongoing rights issue. As a result, the subscription period for the rights issue has been extended by one week to give investors more time to consider their investments. The updated timetable for the rights issue includes specific trading and subscription periods for Sweden and Finland. Eevia Health, founded in 2017, produces bioactive compounds from renewable plant materials and operates a green-chemistry production facility in Finland. The company's shares are listed on the Spotlight Stock Market in Sweden. The press release emphasizes that it does not constitute an offer to trade securities in jurisdictions where such actions would violate laws and highlights that no prospectus will be prepared for the rights issue.

Eevia Health PLC has announced a strategic reorientation and a rights issue of shares totaling approximately SEK 12.1 million, as decided by the board on January 17, 2025. An investment teaser detailing the company's business, products, strategy, and the rights issue is available on Eevia Health's website. The rights issue will involve trading in subscription rights from January 28 to February 6, 2025, with subscription periods in Sweden and Finland from January 28 to February 11 and January 29 to February 13, respectively. The estimated date for announcing the outcome of the rights issue is February 17, 2025. Eevia Health, founded in 2017, focuses on developing bioactive compounds from renewable plant materials for health areas such as gut, kidney, and urinary health. The company's plant extracts are sold globally as ingredients to dietary supplements and food brands. Eevia Health operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, visit their website or contact CEO Stein Ulve.

Eevia Health Plc has initiated a rights issue to raise approximately SEK 12.1 million, with the subscription period running from 28 January to 11 February 2025 in Sweden and 29 January to 13 February 2025 in Finland. The rights issue offers existing shareholders preferential rights to subscribe to new shares, with a subscription price of SEK 0.09 per share. The company aims to use the funds to repay debt, support working capital, and invest in product research and development. The rights issue is part of a broader strategic plan, including product diversification towards gut, kidney, and urinary health, and divestments of certain assets to new start-ups, Havu Health Oy and Baccus Salas Oy. These divestments aim to streamline operations and focus on higher-margin, scientifically substantiated products. Eevia is also negotiating with creditors to extend debt maturity and stabilize its financial position. The company plans to continue as a specialized provider of bioactive compounds, targeting global health challenges.

Eevia Health PLC has announced the publication of an exemption document related to a rights issue of shares valued at approximately SEK 12.1 million, as decided by the board on January 17, 2025. This document complies with the EU Prospectus Regulation and has been registered with the Finnish Financial Supervisory Authority. Eevia Health, founded in 2017, focuses on producing bioactive compounds from renewable plant materials for health-related applications. The company operates in Finland, utilizing sustainable practices, and sells its plant extracts globally. Eevia's shares are listed on the Spotlight Stock Market in Sweden. For more information, visit their website or contact CEO Stein Ulve.

Eevia Health has received a sales order worth KSEK 638 / KUSD 59 for its organically certified elderberry extract, Feno-Sambucus™ 7 ORGANIC, from a US customer through Select Ingredients, a company based in San Diego, California. The end customer is a young brand owner in the organic supplements and health products sector. The extract is noted for its high bioactivity performance and contains more polyphenols than comparable products. The order is valued at KEUR 56 and is a repeat order. Eevia Health, founded in 2017, focuses on sustainably extracted bioactive compounds for health, operating a green-chemistry production facility in Finland. The company is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA.

Eevia Health Plc announced its intention to conduct a rights issue of shares to raise approximately SEK 12.1 million to fund its strategic reorientation and turnaround plan. The rights issue will offer preferential rights to existing shareholders, allowing them to subscribe for new shares. The subscription price is set at SEK 0.09 per share. The rights issue is partially secured by external investors who have committed to underwriting 27% of the total amount. The funds raised will be used for debt repayment, working capital, and investment in product development and equipment. Eevia is undergoing a strategic shift to focus on high-margin health products related to gut, kidney, and urinary health. This includes the development of new products such as MaxBIOME™, ProURO™, and ProRENIS™. The company plans to divest certain assets related to wood-based products and berry-based extracts to new startups, Havu Health Oy and Baccus Salas Oy, respectively. These divestments are part of Eevia's plan to streamline operations and achieve financial stability. The rights issue subscription period runs from 28 January to 11 February 2025 in Sweden and from 29 January to 13 February 2025 in Finland. Trading in subscription rights will occur from 28 January to 6 February 2025. No prospectus will be prepared; instead, an exemption document will be published. The company is also negotiating with creditors to extend debt maturity profiles and obtain consent for divestments, aiming for a healthier liquidity profile in 2025.

At the Extraordinary General Meeting of Shareholders of Eevia Health Plc, held on January 17, 2024, in Seinäjoki, Finland, shareholders authorized the Board of Directors to issue shares, options, and other special rights. This authorization allows for the issuance of up to 180,000,000 shares and can be executed in deviation from shareholders' preemptive rights if justified by a significant financial reason. The authorization remains valid until June 30, 2025. Eevia Health, established in 2017, produces bioactive compounds from renewable plant materials, focusing on gut and related health areas. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA. For more information, contact CEO Stein Ulve or visit their website.

Eevia Health Plc plans to divest €2.5 - 3.0 million worth of equipment related to its berry-based ingredient manufacturing to Baccas Salus Oy, a start-up in Kemijärvi, Finland. This move aims to capitalize on market opportunities that Eevia cannot pursue with its current resources. Baccas Salus will compensate most of the divestment with shares, which Eevia will distribute as dividends to its shareholders, and a smaller portion in cash to help pay down Eevia's debt. Eevia has developed expertise in berry extract manufacturing and sees potential for growth, but its current facility limits cost-efficiency. The divestment will allow Eevia to focus on high-margin gut health products, while Baccas Salus will build a new energy-efficient facility to manufacture a wide range of berry products. The restructuring involves cooperation negotiations with employees and creditor approval. Eevia will continue to seek non-dilutive funding for its projects and plans to sell wood-based ingredients to Havu Health in 2025. The strategy aims to provide Eevia's shareholders with multiple opportunities for success.

Eevia Health Plc plans to divest assets related to Retinari™, a promising eye health compound, by transferring them to a new start-up, Havu Health Oy. This move aims to better manage and fund the development of Retinari™, which has shown potential in combating Age-related Macular Degeneration (AMD). Due to limited resources, Eevia is focusing on faster-to-market products in gut health. Despite investing significantly in Retinari™ and receiving European recognition, Eevia has struggled to secure further funding, stalling the project. Havu Health, co-founded by Eevia's CTO, will seek additional funding and conduct necessary studies for Retinari™. Eevia will receive shares in Havu Health, which will be distributed to its shareholders as a tax-free dividend. Eevia is exploring options to provide liquidity for these shares.

Eevia Health Plc is enhancing its turnaround plan by collaborating with Konsulttiyhtymä AIKA to focus on revenue generation and market opportunities in gut and microbiome health. The company is leveraging high-strength bioactive proanthocyanidin formulas to build a stronger market presence. Recognizing the importance of gut health, Eevia plans to introduce its product MaxBIOME™, which uses berry extracts to support beneficial gut bacteria and combat pathogens. Pre-clinical research indicates potential benefits for gut health, and Eevia is seeking funding for a clinical study. The product is expected to launch in late 2025. Eevia is also exploring bioactives for urinary health, targeting a product launch in early 2026. The company, founded in 2017, focuses on bioactive compounds from sustainable plant materials and operates a production facility in Finland. Eevia's shares are listed on the Spotlight Stock Market in Sweden.